Τhis observation is consistent with the results of clinical trials of SGLT2 inhibitors in other populations such as those with chronic renal disease or type II diabetes mellitus, in which there was no interaction between the effect and BMI [17, 18]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.